Dataset Information


Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management.

ABSTRACT: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial and venous thrombotic manifestations and/or pregnancy-related complications in patients with persistently high antiphospholipid antibodies (aPL), the most common being represented by anticardiolipin antibodies (aCL), anti-beta 2 glycoprotein-I (a?2GPI), and lupus anticoagulant (LAC). A growing number of studies have showed that, in some cases, patients may present with clinical features of APS but with temporary positive or persistently negative titers of aPL. For these patients, the definition of seronegative APS (SN-APS) has been proposed. Nevertheless, the negativity to classic aPL criteria does not imply that other antibodies may be present or involved in the onset of thrombosis. The diagnosis of SN-APS is usually made by exclusion, but its recognition is important to adopt the most appropriate anti-thrombotic strategy to reduce the rate of recurrences. This research is in continuous development as the clinical relevance of these antibodies is far from being completely clarified. The most studied antibodies are those against phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphatidylinositol, vimentin/cardiolipin complex, and annexin A5. Moreover, the assays to measure the levels of these antibodies have not yet been standardized. In this review, we will summarize the evidence on the most studied non-criteria aPL, their potential clinical relevance, and the antithrombotic therapeutic strategies available in the setting of APS and SN-APS.

SUBMITTER: Pignatelli P 

PROVIDER: S-EPMC7049333 | BioStudies | 2020-01-01


REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC6698865 | BioStudies
2018-01-01 | S-EPMC5889035 | BioStudies
2015-01-01 | S-EPMC4877624 | BioStudies
2020-01-01 | S-EPMC7035660 | BioStudies
2019-01-01 | S-EPMC6611479 | BioStudies
2019-01-01 | S-EPMC6794730 | BioStudies
2020-01-01 | S-EPMC6978159 | BioStudies
2020-01-01 | S-EPMC7065342 | BioStudies
2020-01-01 | S-EPMC7593765 | BioStudies
2020-01-01 | S-EPMC7724273 | BioStudies